Identification of antimony resistance markers in Leishmania tropica field isolates through a cDNA-AFLP approach

Experimental Parasitology

Volumn 135, Issue 2, 2013, Pages 344-349

  Kazemi Rad, Elham ^a   Mohebali, Mehdi ^a   Erfan, Mohammad Bagher Khadem ^a   Saffari, Mojtaba ^a   Raoofian, Reza ^a,b   Hajjaran, Homa ^a   Hadighi, Ramtin ^c   Khamesipour, Ali ^d   Rezaie, Sassan ^a   Abedkhojasteh, Hoda ^a   Heidari, Mansour ^a,e  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Antimony resistance; CDNA AFLP; Leishmania tropica; Real time RT PCR

Indexed keywords

ABC TRANSPORTER; MEGLUMINE ANTIMONATE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN TYROSINE PHOSPHATASE;

AMPLIFIED FRAGMENT LENGTH POLYMORPHISM; ANTIMALARIAL DRUG RESISTANCE; ANTIMALARIAL DRUG SUSCEPTIBILITY; AQUAGLYCEROPORIN 1 GENE; ARTICLE; ATP BINDING CASSETTE TRANSPORTER GENE; CDNA AMPLIFIED FRAGMENT LENGTH POLYMORPHISM; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; LEISHMANIA TROPICA; MITOGEN ACTIVATED PROTEIN KINASE GENE; NONHUMAN; PHOSPHOGLYCERATE KINASE B GENE; PRIORITY JOURNAL; PROTEIN TYROSINE PHOSPHATASE GENE; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

ANTIMONY RESISTANCE; CDNA-AFLP; LEISHMANIA TROPICA; REAL-TIME RT-PCR;

AMPLIFIED FRAGMENT LENGTH POLYMORPHISM ANALYSIS; ANTIMONY; ANTIPROTOZOAL AGENTS; CELL LINE; DNA FRAGMENTATION; DNA, COMPLEMENTARY; DNA, PROTOZOAN; DRUG RESISTANCE; GENES, PROTOZOAN; INHIBITORY CONCENTRATION 50; LEISHMANIA TROPICA; MEGLUMINE; ORGANOMETALLIC COMPOUNDS; PARASITIC SENSITIVITY TESTS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, PROTOZOAN;

EID: 84883371716     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2013.07.018     Document Type: Article

References (49)

1. Alvar J., Vélez I.D., Bern C., Herrero M., Desjeux P., Cano J., Jannin J., Boer M.D. Leishmaniasis worldwide and global estimates of its incidence. PLoS One 2012, 7:e35671. The WHOLCT.
2. Andreeva A.V., Kutuzov M.A. Protozoan protein tyrosine phosphatases. Int. J. Parasitol. 2008, 38:1279-1295.
3. Ashutosh M.G., Sundar S., Duncan R., Nakhasi H.L., Goyal N. Downregulation of mitogen-activated protein kinase 1 of Leishmania donovani field isolates is associated with antimony resistance. Antimicrob. Agents Chemother. 2012, 56:518-525.
4. Biyani N., Singh A.K., Mandal S., Chawla B., Madhubala R. Differential expression of proteins in antimony-susceptible and -resistant isolates of Leishmania donovani. Mol. Biochem. Parasitol. 2011, 179:91-99.
5. Callahan H.L., Portal A.C., Devereaux R., Grogl M. An axenic amastigote system for drug screening. Antimicrob. Agents Chemother. 1997, 41:818-822.
6. Decuypere S., Rijal S., Yardley V., De Doncker S., Laurent T., Khanal B., Chappuis F., Dujardin J.C. Gene expression analysis of the mechanism of natural Sb(V) resistance in Leishmania donovani isolates from Nepal. Antimicrob. Agents Chemother. 2005, 49:4616-4621.
7. Denton H., McGREGOR J.C., Coombs G.H. Reduction of anti-leishmanial pentavalent antimonial drugs by a parasite-specific thiol-dependent reductase, TDR1. Biochem. J. 2004, 381:405.
8. Desagher S., Glowinski J., Prémont J. Pyruvate protects neurons against hydrogen peroxide-induced toxicity. J. Neurosci. 1997, 17:9060-9067.
9. Do Monte-Neto R.L., Coelho A.C., Raymond F., Legare D., Corbeil J., Melo M.N., Frezard F., Ouellette M. Gene expression profiling and molecular characterization of antimony resistance in Leishmania amazonensis. PLoS Negl. Trop. Dis. 2011, 5:e1167.
10. El Fadili K., Drummelsmith J., Roy G., Jardim A., Ouellette M. Downregulation of KMP-11 in Leishmania infantum axenic antimony resistant amastigotes as revealed by a proteomic screen. Exp. Parasitol. 2009, 123:51-57.
11. El Fadili K., Messier N., Leprohon P., Roy G., Guimond C., Trudel N., Saravia N.G., Papadopoulou B., Legare D., Ouellette M. Role of the ABC transporter MRPA (PGPA) in antimony resistance in Leishmania infantum axenic and intracellular amastigotes. Antimicrob. Agents Chemother. 2005, 49:1988-1993.
12. Farahyar S., Zaini F., Kordbacheh P., Rezaie S., Safara M., Raoofian R., Heidari M. Overexpression of aldo-keto-reductase in azole-resistant clinical isolates of Candida glabrata determined by cDNA-AFLP. DARU 2013, 21:1.
13. Gourbal B., Sonuc N., Bhattacharjee H., Legare D., Sundar S., Ouellette M., Rosen B.P., Mukhopadhyay R. Drug uptake and modulation of drug resistance in Leishmania by an aquaglyceroporin. J. Biol. Chem. 2004, 279:31010-31017.
14. Grondin K., Haimeur A., Mukhopadhyay R., Rosen B.P., Ouellette M. Co-amplification of the γ-glutamylcysteine synthetase gene gsh1 and of the ABC transporter gene pgpA in arsenite-resistant Leishmania tarentolae. EMBO J. 1997, 16:3057-3065.
15. Hadighi R., Mohebali M., Boucher P., Hajjaran H., Khamesipour A., Ouellette M. Unresponsiveness to Glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites. PLoS Med. 2006, 3:e162.
16. Haimeur A., Guimond C., Pilote S., Mukhopadhyay R., Rosen B.P., Poulin R., Ouellette M. Elevated levels of polyamines and trypanothione resulting from overexpression of the ornithine decarboxylase gene in arsenite-resistant Leishmania. Mol. Microbiol. 1999, 34:726-735.
17. Hajjaran H., Azarian B., Mohebali M., Hadighi R., Assareh A., Vaziri B. Comparative proteomics study on meglumine antimoniate sensitive and resistant Leishmania tropica isolated from Iranian anthroponotic cutaneous leishmaniasis patients. East. Mediterr. Health J. 2012, 18:165-171.
18. Hajjaran H., Mohebali M., Razavi M., Rezaei S., Kazemi B., Edrissian G.H., Mojtabavi J., Hooshmand B. Identification of Leishmania species isolated from human cutaneous leishmaniasis, using random amplified polymorphic DNA (RAPD-PCR). Iran. J. Public Health 2004, 33:8-15.
19. Kedzierski L., Sakthianandeswaren A., Curtis J.M., Andrews P.C., Junk P.C., Kedzierska K. Leishmaniasis: current treatment and prospects for new drugs and vaccines. Curr. Med. Chem. 2009, 16:599-614.
20. Khatami A., Firooz A., Gorouhi F., Dowlati Y. Treatment of acute old world cutaneous leishmaniasis: a systematic review of the randomized controlled trials. J. Am. Acad. Dermatol. 2007, 57(335):e1-29.
21. Kim H.S., Song M.C., Kwak I.H., Park T.J., Lim I.K. Constitutive induction of p-Erk1/2 accompanied by reduced activities of protein phosphatases 1 and 2A and MKP3 due to reactive oxygen species during cellular senescence. J. Biol. Chem. 2003, 278:37497-37510.
22. Kumar A., Sisodia B., Misra P., Sundar S., Shasany A.K., Dube A. Proteome mapping of overexpressed membrane-enriched and cytosolic proteins in sodium antimony gluconate (SAG) resistant clinical isolate of Leishmania donovani. Br. J. Clin. Pharmacol. 2010, 70:609-617.
23. Légaré D., Richard D., Mukhopadhyay R., Stierhof Y.D., Rosen B.P., Haimeur A., Papadopoulou B., Ouellette M. The Leishmania ATP-binding cassette protein PGPA is an intracellular metal-thiol transporter ATPase. J. Biol. Chem. 2001, 276:26301-26307.
24. Leonard S.S., Harris G.K., Shi X. Metal-induced oxidative stress and signal transduction. Free Radic. Biol. Med. 2004, 37:1921-1942.
25. -δδct Method. Methods 2001, 25:402-408.
26. Mandal S., Maharjan M., Singh S., Chatterjee M., Madhubala R. Assessing aquaglyceroporin gene status and expression profile in antimony-susceptible and -resistant clinical isolates of Leishmania donovani from India. J. Antimicrob. Chemother. 2010, 65:496-507.
27. Mann K.K., Davison K., Colombo M., Colosimo A.L., Diaz Z., Padovani A.M., Guo Q., Scrivens P.J., Gao W., Mader S., Miller W.H. Antimony trioxide-induced apoptosis is dependent on SEK1/JNK signaling. Toxicol. Lett. 2006, 160:158-170.
28. Mansouri A., Ridgway L.D., Korapati A.L., Zhang Q., Tian L., Wang Y., Siddik Z.H., Mills G.B., Claret F.X. Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J. Biol. Chem. 2003, 278:19245-19256.
29. Marquis N., Gourbal B., Rosen B.P., Mukhopadhyay R., Ouellette M. Modulation in aquaglyceroporin AQP1 gene transcript levels in drug-resistant Leishmania. Mol. Microbiol. 2005, 57:1690-1699.
30. Mukherjee A., Padmanabhan P.K., Singh S., Roy G., Girard I., Chatterjee M., Ouellette M., Madhubala R. Role of ABC transporter MRPA, gamma-glutamylcysteine synthetase and ornithine decarboxylase in natural antimony-resistant isolates of Leishmania donovani. J. Antimicrob. Chemother. 2007, 59:204-211.
31. Murray H.W., Berman J.D., Davies C.R., Saravia N.G. Advances in leishmaniasis. Lancet 2005, 366:1561-1577.
32. Nascimento M., Zhang W.W., Ghosh A., Houston D.R., Berghuis A.M., Olivier M., Matlashewski G. Identification and characterization of a protein-tyrosine phosphatase in Leishmania: Involvement in virulence. J. Biol. Chem. 2006, 281:36257-36268.
33. Opperdoes F.R., Coombs G.H. Metabolism of Leishmania: proven and predicted. Trends Parasitol. 2007, 23:149-158.
34. Pathak M.K., Yi T. Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines. J. Immunol. 2001, 167:3391-3397.
35. Saffari M., Dinehkabodi O.S., Ghaffari S.H., Modarressi M.H., Mansouri F., Heidari M. Identification of novel p53 target genes by cDNA-AFLP in glioblastoma cells. Cancer Lett. 2009, 273:316-322.
36. Schaeffer H.J., Weber M.J. Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol. Cell. Biol. 1999, 19:2435-2444.
37. Sereno D., Cavaleyra M., Zemzoumi K., Maquaire S., Ouaissi A., Lemesre J. Axenically grown amastigotes ofLeishmania infantum used as an in vitro model to investigate the pentavalent antimony mode of action. Antimicrob. Agents Chemother. 1998, 42:3097-3102.
38. Shaked-Mishan P., Ulrich N., Ephros M., Zilberstein D. Novel intracellular SbV reducing activity correlates with antimony susceptibility in Leishmania donovani. J. Biol. Chem. 2001, 276:3971-3976.
39. Singh R., Kumar D., Duncan R.C., Nakhasi H.L., Salotra P. Overexpression of histone H2A modulates drug susceptibility in Leishmania parasites. Int. J. Antimicrob. Agents 2010, 36:50-57.
40. Sundar S. Drug resistance in Indian visceral leishmaniasis. Trop. Med. Int. Health 2002, 6:849-854.
41. Tonks N.K. PTP1B: from the sidelines to the front lines!. FEBS Lett. 2003, 546:140-148.
42. Vergnes B., Gourbal B., Girard I., Sundar S., Drummelsmith J., Ouellette M. A proteomics screen implicates HSP83 and a small kinetoplastid calpain-related protein in drug resistance in Leishmania donovani clinical field isolates by modulating drug-induced programmed cell death. Mol. Cell Proteomics 2007, 6:88-101.
43. Vuylsteke M., Peleman J.D., van Eijk M.J. AFLP-based transcript profiling (cDNA-AFLP) for genome-wide expression analysis. Nat. Protoc. 2007, 2:1399-1413.
44. Walker J., Gongora R., Vasquez J.J., Drummelsmith J., Burchmore R., Roy G., Ouellette M., Gomez M.A., Saravia N.G. Discovery of factors linked to antimony resistance in Leishmania panamensis through differential proteome analysis. Mol. Biochem. Parasitol. 2012, 183:166-176.
45. Yaghoobi-Ershadi M.R., Akhavan A.A., Zahraei-Ramazani A.V., Abai M.R., Ebrahimi B., Vafaei-Nezhad R., Hanafi-Bojd A.A., Jafari R. Epidemiological study in a new focus of cutaneous leishmaniasis in the Islamic Republic of Iran. East. Mediterr. Health J. 2003, 9:816-826.
46. Yaghoobi-Ershadi M.R., Hanafi-Bojd A.A., Javadian E., Jafari R., Zahraei-Ramazani A.R., Mohebali M. A new focus of cutaneous leishmaniasis caused by Leishmania tropica. Saudi Med. J. 2002, 23:291-294.
47. Yan S., Li F., Ding K., Sun H. Reduction of pentavalent antimony by trypanothione and formation of a binary and ternary complex of antimony (III) and trypanothione. J. Biol. Inorg. Chem. 2003, 8:689-697.
48. Yang D., Ma P., Liang X., Liang Z., Zhang M., Shen S., Liu H., Liu Y. Metabolic profiles and cDNA-AFLP analysis of Salvia miltiorrhiza and Salvia castanea Diel f. tomentosa Stib. PLoS One 2012, 7:e29678.
49. Zhou Y., Messier N., Ouellette M., Rosen B.P., Mukhopadhyay R. Leishmania major LmACR2 is a pentavalent antimony reductase that confers sensitivity to the drug pentostam. J. Biol. Chem. 2004, 279:37445-37451.